« Back to Medicines list

Naseptin Nasal Cream

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 27/03/19

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 22/3/2019

Click on this link to Download PDF directly

Alliance Pharmaceuticals Ireland

Alliance Pharmaceuticals Ireland

Company Products

Medicine NameActive Ingredients
Medicine Name Ametop 40 mg/g Gel Active Ingredients Tetracaine hydrochloride
Medicine Name Anbesol Anaesthetic Antiseptic Oromucosal Solution Active Ingredients Cetylpyridinium Chloride, Chlorocresol, Lidocaine Hydrochloride
Medicine Name Haemopressin 1 mg powder and solvent for solution for injection Active Ingredients Terlipressin acetate
Medicine Name Naseptin Nasal Cream Active Ingredients Chlorhexidine Dihydrochloride, Neomycin sulfate
Medicine Name Nu-Seals 300 Active Ingredients Aspirin
Medicine Name Nu-Seals 75 Active Ingredients Aspirin
Medicine Name Occlusal Active Ingredients Salicylic Acid
Medicine Name Quinoderm 10% w/w + 0.5% w/w Cream Active Ingredients Benzoyl Peroxide, hydrous, Potassium hydroxyquinoline sulfate
Medicine Name Quinoderm 5% w/w + 0.5% w/w Cream Active Ingredients Benzoyl Peroxide, hydrous, Potassium hydroxyquinoline sulfate
Medicine Name Ranitidine 50mg/2ml Solution for Injection and Infusion Active Ingredients Ranitidine Hydrochloride
Medicine Name Syntometrine injection Active Ingredients Ergometrine Maleate, Oxytocin
1 - 0 of 11 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 27 March 2019 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder

Updated on 22 March 2019 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder

Updated on 22 March 2019 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 20 July 2018 SmPC

Reasons for updating

  • File format updated to PDF

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

File format update to PDF

Updated on 29 October 2014 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 29 October 2014 SmPC

Reasons for updating

  • Correction of spelling/typing errors
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change spelling of Sulphate to Sulfate
Addition of reporting of  ADR statement
IMB name change

Updated on 28 October 2014 PIL

Reasons for updating

  • New PIL for new product

Updated on 28 October 2014 PIL

Reasons for updating

  • Addition of information on reporting a side effect.
  • Correction of spelling/typing errors

Updated on 22 October 2014 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 23 January 2013 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Changes highlighted in red below:

 

4.8 Undesirable effects

Undesirable effects are listed by MedDRA System Organ Classes.

Assessment of undesirable effects is based on the following frequency groupings:
Very common: ≥1/10
Common: ≥1/100 to <1/10
Uncommon: ≥1/1,000 to <1/100
Rare: ≥1/10,000 to <1/1,000
Very rare: <1/10,000

Not known: cannot be estimated from the available data

 

 

System Organ Class

Frequency

 

 

Undesirable Effect

 

 

Immune system disorders

 

 

 

Not known

 

 

 

ï‚·

 

anaphylaxis, hypersensitivity

 

Nervous system disorders

 

 

 

Not known

 

 

 

ï‚·

 

temporary hyposmia

 

ï‚·

 

temporary ageusia

 

Ear and labyrinth disorders

 

 

 

Not known

 

 

 

ï‚·

 

ototoxicity1

 

Skin and subcutaneous tissue disorders

 

 

 

Not known

 

 

 

ï‚·

 

Irritative skin reactions

 

ï‚·

 

skin sensitisation

 

Renal and urinary disorders

 

 

 

Not known

 

 

 

ï‚·

 

nephrotoxicity

 

1

 

Use with caution in children, elderly patients and patients with impaired hearing (see Section 4.4 ‘Special warnings and precautions for use’).

 

Local irritation and hypersensitivity can occasionally occur.

Prolonged use may lead to skin sensitisation to neomycin.

Anaphylaxis to chlorhexidine has been reported rarely.

Updated on 21 January 2013 PIL

Reasons for updating

  • Change to side-effects

Updated on 15 August 2011 PIL

Reasons for updating

  • Change to side-effects
  • Change due to user-testing of patient information

Updated on 4 May 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Additions/Changes higlighted in red text:

2.                  QUALITATIVE AND QUANTITATIVE COMPOSITION

 

            Chlorhexidine dihydrochloride         0.1       %w/w

            Neomycin Sulphate                       0.5       %w/w (3250 IU/g)

 

            Excipients: Contains 8% w/w (80mg/g) cetostearyl alcohol

 

            For a full list of excipients, see section 6.1.

 

4.3             Contraindications

 

Hypersensitivity to chlorhexidine and neomycin or to any of the excipients.

            Some patients have shown a hypersensitivity reaction to neomycin or chlorhexidine, although such reactions are extremely rare. 

4.8             Undesirable effects

 

            Local irritation and hypersensitivity can occasionally occur.

 

            Prolonged use may lead to skin sensitisation to neomycin.

 

            Anaphylaxis to chlorhexidine has been reported rarely.


 

5.1             Pharmacodynamic properties

 

            Pharmacotherapeutic group: Other antibiotics for topical use

 

            ATC code: D06AX

 

         

Updated on 8 March 2011 PIL

Reasons for updating

  • Change to side-effects
  • Change to further information section
  • Change to date of revision

Updated on 4 January 2010 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2: The active ingredient has changed from chlorhexidine hydrochloride to chlorhexidine dihydrochloride

Updated on 23 December 2009 PIL

Reasons for updating

  • Change of trade or active ingredient name

Updated on 22 July 2008 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 17 June 2008 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to name of manufacturer
  • Change to storage instructions

Updated on 16 June 2008 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.4 - Special precautions for storage
  • Change to improve clarity and readability

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 1. Now reads
Naseptin 0.1% & 0.5% w/w Nasal Cream
 
Section 2. Now reads

Chlorhexidine Hydrochloride           0.1       %w/w

Neomycin Sulphate                           0.5       %w/w

 

Excipients: Contains 8% w/w (80mg/g) cetostearyl alcohol

 

For a full list of excipients, see section 6.1.
 
Section 6.4. Now reads

Do not store above 30ºC.  Keep the tube tightly closed. Keep the tube in the outer carton.

Updated on 22 December 2006 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4  
Naseptin contains Arachis oil (peanut oil) and should not be taken/applied by patients known to be allergic to peanut. As there is a possible relationship between allergy to peanut and allergy to Soya, patients with Soya allergy should also avoid Naseptin, has been removed.

 

Section 6.1
Excipients changed to medium-chain triglycerides instead of arachis oil.

Updated on 22 December 2006 PIL

Reasons for updating

  • Change of inactive ingredient

Updated on 27 November 2006 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The arachis oil excipient has been removed and replaced with medium chain triglycerides

Updated on 16 May 2005 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 9 March 2005 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 30 July 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 23 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)